In the current study, we examined the pharmacokinetics and patterns of THK5351 uptake, and putative tau accumulation, in AD participants and in healthy control (HC) participants, to provide a more thorough understanding of this tracer, and potential processing and analysis considerations for any future researchers using this or related tracers. Here, MAPT is linked to Alzheimer disease.